Intellectual Property India Publishes Patent Application for Solid Forms Comprising (5r,6s)-10,11-Difluoro-12-((2-Fluoro-4-Iodophenyl)amino)-5,6-Dihydroxy-4,5,6,7- Tetrahydro-1h-Spiro[benzo[b][1,5,4]oxathiazecine-3,1'-Cyclopropane] 2,2-Dioxide, And Compositions Comprising And Methods Of Using The Same

MUMBAI, India, Aug. 12 -- Intellectual Property India has published a patent application (202647091960 A) filed by Pasithea Therapeutics Corp. on July 29, 2026, for Solid Forms Comprising (5r,6s)-10,11-Difluoro-12-((2-Fluoro-4-Iodophenyl)amino)-5,6-Dihydroxy-4,5,6,7- Tetrahydro-1h-Spiro[benzo[b][1,5,4]oxathiazecine-3,1'-Cyclopropane] 2,2-Dioxide, And Compositions Comprising And Methods Of Using The Same.

Inventors include Lazarus, Mathew; Marques, Tiago, Reis; Jiang, Siyi; Gao, Ming; Sun, Lele; and Khire, Uday.

The application for the patent was published on August 07, 2026, under issue no. 32/2026.

Abstract: Described herein are solid forms of (5R,6S)-10,11-difluoro-12-((2-fluoro-4- iodophenyl)amino)-5,6-dihydroxy -4,5,6, 7 -tetrahydro- 1H-spiro[benzo[b] [1,5, 4]oxathiazecine- 3,1'-cyclopropane] 2,2-dioxide in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating a disease or disorder in which the RAS pathway is upregulated such as cancer, RASopathies and laminopathies. Formula (I).

Disclaimer: Curated by HT Syndication.